Skip to content

Alumis Inc. ALMS Contract Liabilities, Non-Current

Contract Liabilities, Non-Current at other companies

Kymera Therapeutics logo
Kymera TherapeuticsKYMR
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.17B+739%

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s contract liabilities, non-current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alumis Inc.'s contract liabilities, non-current?
Alumis Inc. (ALMS) reported contract liabilities, non-current of $2.61M in Q4 2025.